Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Greil

Showing results (21-30 of 525) with videos related to

Pageof 53
Sort By:
Memo|January 1, 2019
ASCO 2018 highlights: metastatic breast cancerGabriel Rinnerthaler, Simon Peter Gampenrieder, Richard Greil
Memo|December 19, 2017
Antiangiogenic therapy in breast cancerSimon Peter Gampenrieder, Theresa Westphal, Richard Greil
Memo|July 19, 2016
CDK4/6 inhibition in luminal breast cancerSimon Peter Gampenrieder, Gabriel Rinnerthaler, Richard Greil
Breast Care (Basel, Switzerland)|March 12, 2015
Bone-targeted therapy in metastatic breast cancer - all well-established knowledge?Simon P Gampenrieder, Gabriel Rinnerthaler, Richard Greil
Memo|July 21, 2017
SABCS 2016: systemic therapy for metastatic breast cancerSimon Peter Gampenrieder, Gabriel Rinnerthaler, Richard Greil
Journal of Leukocyte Biology|September 2, 2003
Tracking death dealing by Fas and TRAIL in lymphatic neoplastic disorders: pathways, targets, and therapeutic toolsRichard Greil, Gabriele Anether, Karin Johrer, et al.
Critical Reviews in Immunology|January 1, 2004
Tuning the rheostat of the myelopoietic system via Fas and TRAILRichard Greil, Gabriele Anether, Karin Johrer, et al.
Frontiers in Immunology|May 6, 2015
The Role of CD44 in the Pathophysiology of Chronic Lymphocytic LeukemiaJulia Christine Gutjahr, Richard Greil, Tanja Nicole Hartmann
Journal of Gastrointestinal Oncology|May 20, 2021
Ramucirumab plus FOLFIRI or irinotecan as second-line therapy in advanced or metastatic gastric or gastroesophageal junction adenocarcinomaVerena Schlintl, Florian Huemer, Richard Greil, et al.
Breast Care (Basel, Switzerland)|January 14, 2014
Everolimus in postmenopausal, hormone receptor-positive advanced breast cancer: summary and results of an austrian expert panel discussionMichael Gnant, Richard Greil, Michael Hubalek, et al.
Pageof 53

Showing results (21-30 of 525) with videos related to

Sort By:
Pageof 53
Memo|January 1, 2019
ASCO 2018 highlights: metastatic breast cancerGabriel Rinnerthaler, Simon Peter Gampenrieder, Richard Greil
Memo|December 19, 2017
Antiangiogenic therapy in breast cancerSimon Peter Gampenrieder, Theresa Westphal, Richard Greil
Memo|July 19, 2016
CDK4/6 inhibition in luminal breast cancerSimon Peter Gampenrieder, Gabriel Rinnerthaler, Richard Greil
Breast Care (Basel, Switzerland)|March 12, 2015
Bone-targeted therapy in metastatic breast cancer - all well-established knowledge?Simon P Gampenrieder, Gabriel Rinnerthaler, Richard Greil
Memo|July 21, 2017
SABCS 2016: systemic therapy for metastatic breast cancerSimon Peter Gampenrieder, Gabriel Rinnerthaler, Richard Greil
Journal of Leukocyte Biology|September 2, 2003
Tracking death dealing by Fas and TRAIL in lymphatic neoplastic disorders: pathways, targets, and therapeutic toolsRichard Greil, Gabriele Anether, Karin Johrer, et al.
Critical Reviews in Immunology|January 1, 2004
Tuning the rheostat of the myelopoietic system via Fas and TRAILRichard Greil, Gabriele Anether, Karin Johrer, et al.
Frontiers in Immunology|May 6, 2015
The Role of CD44 in the Pathophysiology of Chronic Lymphocytic LeukemiaJulia Christine Gutjahr, Richard Greil, Tanja Nicole Hartmann
Journal of Gastrointestinal Oncology|May 20, 2021
Ramucirumab plus FOLFIRI or irinotecan as second-line therapy in advanced or metastatic gastric or gastroesophageal junction adenocarcinomaVerena Schlintl, Florian Huemer, Richard Greil, et al.
Breast Care (Basel, Switzerland)|January 14, 2014
Everolimus in postmenopausal, hormone receptor-positive advanced breast cancer: summary and results of an austrian expert panel discussionMichael Gnant, Richard Greil, Michael Hubalek, et al.
Pageof 53